Harpoon Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Harpoon Therapeutics generated cash of -$89,182,000, which is more than the previous year. Cash used in financing activities reached the amount of $6,372,000 last year. Net change in cash is therefore $6,927,000.
Cash Flow
| 2016 | -10.79M | -553K | 9.98M |
|---|---|---|---|
| 2017 | 1.71M | 4.47M | 22.24M |
| 2018 | -27.12M | -663K | 88.32M |
| 2019 | -2.89M | -69.31M | 71.44M |
| 2020 | -8.61M | -63.62M | 4.67M |
| 2021 | -122.15M | 34.35M | 111.52M |
| 2022 | -89.18M | 89.73M | 6.37M |
HARP Cash Flow Statement (2016 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 45.36M | 21.63M | 89.20M | 89.96M | 29.42M | 985K | 2.34M |
Operating activities | |||||||
Net income | -67.73M | -116.72M | -49.90M | -55.57M | -27.36M | -16.83M | -11.40M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 2.35M | 2.19M | 2.08M | 900K | 644K | 366K | 198K |
Stock-based compensation expense | 8.63M | 9.46M | 4.86M | 2.07M | 672K | 367K | 99K |
| Deferred income tax benefit | 8.63M | 9.46M | 4.86M | 2.07M | 672K | 367K | 99K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.04M | 542K | -1.22M | -1.76M | 2.55M | 804K | 570K |
Cash generated by operating activities | -89.18M | -122.15M | -8.61M | -2.89M | -27.12M | 1.71M | -10.79M |
Investing activities | |||||||
Purchases Of Investments | -24.42M | -151.96M | -202.18M | -141.81M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -347K | -100K | -683K | -3.51M | -663K | -2.27M | -553K |
Acquisitions Net | -89.73M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 89.73M | 34.35M | -63.62M | -69.31M | -663K | 4.47M | -553K |
Financing activities | |||||||
Common Stock Issued | 5.38M | 110.34M | 3.03M | 70.64M | 89.82M | 2K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 6.37M | 111.52M | 4.67M | 71.44M | 88.32M | 22.24M | 9.98M |
Net Change In Cash | 6.92M | 23.72M | -67.56M | -757K | 60.53M | 28.43M | -1.36M |
Cash at end of period | 52.28M | 45.36M | 21.63M | 89.20M | 89.96M | 29.42M | 985K |
| Data source | Data source | Data source | Data source | Data source |